Navigation Links
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Date:8/28/2008

CEO. His significant international management experience and his contribution to the Company's success over the last eighteen months gives me great confidence that ThromboGenics will continue to prosper under his leadership. I am looking forward to serving ThromboGenics where I believe I can make further important contributions to the Company's success given the exciting science that is being carried out in both our labs and those of our partners."

For further information please contact:

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development by the end of 2008, and TB-403 (Anti-PlGF). ThromboGenics and its development partner BioInvent, have recently signed a license agreement with Roche for TB-403 worth up to EUR500 million plus royalties. A Phase Ib clinical trial with TB-403 has recently begun in patients with late stage cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
2. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
3. ThromboGenics N.V. - Business Update
4. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
5. ThromboGenics Announces 2007 Full Year Results
6. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
9. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
10. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
11. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Can economic incentives such as gift cards, T-shirts, ... public to increase their donations of blood? , A ... School Assistant Professor Mario Macis says the answer ... of recent research that supports their argument, the three ... Science that the World Health Organization and national blood ...
(Date:5/23/2013)... May 23, 2013 The maker community ... types of inventions. They focus on learning practical skills ... community gravitate toward bringing their ideas to life via ... Movement, works on making projects using biology. Glowing Plant ... plants to make them glow with bioluminescence genes, and ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... SOUTH EASTON, Mass. , May 23, 2013 /PRNewswire/ ... "Company") today announced that the Company will host a ... and to provide a business update. The teleconference information ... 2013 Time: 11:00 a.m. Eastern Daylight Time (EDT) ... Canada ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... June 29 Centocor Ortho Biotech Inc. announced today that ... against Abbott Laboratories in a patent infringement suit. , ... our favor in the patent litigation case against Abbott," said ... in question relates to the company,s anti-TNF class of arthritis ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical ... it was added to the Russell 3000 and Russell 2000 ... June 29, 2009. The Russell family of U.S. indexes is ... of the investable U.S. equity market. , , The ...
... SGP ) is scheduled to announce its sales and earnings ... , , At approximately 7:45 a.m. (EDT) on ... for the 2009 second quarter. Fred Hassan, Schering-Plough,s chairman and ... , , To listen live to the call, dial ...
Cached Biology Technology:Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories 2BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes 2Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings 2
(Date:5/23/2013)... be the world,s most popular fruit, can be made ... purple GM varieties. , "Working with GM tomatoes ... addition of a specific compound, allows us to pinpoint ... Cathie Martin from the John Innes Centre. , The ... flavour, health and shelf life characteristics because even higher ...
(Date:5/23/2013)... mechanism by which estrogen suppresses lipid synthesis in the ... approach toward treating certain liver diseases. , With ... are changing long-held views in the field. Study results ... Science Signaling . , "The dogma in the ... only receptors located in the nucleus respond to steroid ...
(Date:5/23/2013)... A new report from the Institute of Medicine ... in at least 60 minutes of vigorous or moderate ... than half of American youth meet current evidence-based guidelines ... intensity physical activity daily, according to the report, which ... school for nearly half of their waking hours, the ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide students with daily physical activity, IOM recommends 2
... cameras in our cell phones have dramatically changed the way ... instantly available to friends and family. Now, the imaging sensor ... helping engineers at the California Institute of Technology (Caltech) transform ... platform for a "smart" petri dish. Dubbed ePetri, ...
... more than 100 years ago by Camillo Golgi, the ... as a critical sorting and processing station for intracellular ... endoplasmic reticulum and then dispatches this to the plasma ... such as endosomes. The Golgi also plays an important ...
... of seabird in the Galpagos, the child abuse "cycle of violence" ... study of Nazca boobies by Wake Forest University researchers provides the ... when they are young often grow up to be abusers. ... The Auk . "We were surprised by the ...
Cached Biology News:Caltech engineers build smart petri dish 2Caltech engineers build smart petri dish 3Child abuse in birds: Study documents 'cycle of violence' in nature 2
Includes PROTEAN II xi Basic unit and IPG conversion kit PROTEAN II XL Cell, wide format, Compatible with ReadyStrip IPG Strips 1.0 mm 165-3188 1.5 mm 165-3189 2.0 mm 165-3190...
... cell, 20 cm, is used for vertical slab ... agarose gels. The cell is supplied without spacers ... core with gaskets, lower buffer chamber, lid with ... clamps, upper buffer dam, casting stand with gaskets, ...
... This depletion cocktail is ... T cells from suspensions of ... Cells are separated using the ... negative selection system. The CD4+ ...
... uses the Adept CE 4100 high pressure dual ... dual wavelength detector for added flexibility. ... software and interface unit, CE 4901., The CE ... also be used with Windows 98 and 2000, ...
Biology Products: